Navigation Links
Genetic mutation associated with increased risk of lung cancer
Date:5/26/2008

Carriers of a common genetic disorder previously linked to lung disease may have a 70-percent to 100-percent increased risk of lung cancer, according to a report in the May 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

The disorder, alpha1-antitrypsin deficiency (1ATD), is one of the most common genetic conditions affecting the U.S. population and especially those of European descent, according to background information in the article. Individuals with two copies of the associated genetic mutation often develop emphysema at an early age. However, 1ATD carriersthose with only one copy of the mutated genedo not normally have severe diseases related to 1ATD and may not be aware of their status. However, they may be more vulnerable to cancer-causing tobacco smoke than non-carriers.

Ping Yang, M.D., Ph.D., and colleagues at the Mayo Clinic, Rochester, Minn., tested for 1ATD carrier status in 1,443 patients with lung cancer. In addition, 797 community members without lung cancer and 902 siblings of lung cancer patients were tested as controls. Information was gathered about all participants smoking history, demographic characteristics and family history of cancer.

A total of 13.4 percent of the lung cancer patients and 7.8 percent of unrelated controls were 1ATD carriers. When patients with lung cancer were compared to non-related controls, 1ATD carriers had a 70 percent higher risk of developing lung cancer than non-carriers. Comparing patients with lung cancer to their cancer-free siblings, 1ATD carriers had twice the risk of developing lung cancer. The researchers estimated that 1ATD carrier status may account for 11 percent to 12 percent of the patients with lung cancer enrolled in the study.

Among those who had never smoked, 1ATD carrier status was associated with a 2.2-fold higher risk of lung cancer, with a 2-fold increased risk among light smokers and a 2.3-fold increased risk among moderate
'/>"/>

Contact: Traci Klein
507-284-5005
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... release is available in German . ... infants was investigated using the prominent ,Stanford Marshmallow Experiment,: the children ... eat it now or wait and receive a second one if ... several minutes. Interestingly, children that were able to wait for the ...
... March 13, 2013, Shenzhen, China - In a collaborative study ... Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, ... of wild rice Oryza brachyantha . This work provides ... of Oryza genomes. The genus Oryza ...
... up and walked on two legs is considered to be one ... gone to the far ends of the earth and the ... we walk the way we walk. In the latest such ... Africa) have taken a closer look at bipedal kangaroos and wallabies ...
Cached Biology News:Doing business with a parrot 2Whole genome sequencing of wild rice reveals the mechanisms underlying oryza genome evolution 2It's all in the way we move 2
(Date:4/28/2015)... Showcasing continued leadership in the ... company that provides scientifically advanced, age-defying products, has ... Selling Association (DSA) by the DSA Board of ... period, the DSA confirmed that Nerium’s business practices ... the association: to ensure that direct sales consumers ...
(Date:4/28/2015)... 2015  DanDrit Biotech USA , ... for the treatment of colorectal cancer, is pleased to ... with GISCAD Foundation, a highly recognized Italian group with ... The collaboration relates to VIVA, a Phase III adjuvant ... of disease (NED) Stage IV colorectal cancer (CRC). The ...
(Date:4/28/2015)... 2015  US-Australian drug discovery company, Novogen Limited (ASX: ... a letter from NASDAQ informing it that it had ... Rule). In November 2014, the Company ... to submit a plan to regain compliance with the ... $2,500,000 in stockholders, equity as of June 30, 2014; ...
(Date:4/28/2015)... Calverton, Maryland (PRWEB) April 28, 2015 ... Data Warehouse that bring it to the web ... visualization features and user friendly reporting metrics increase ... save reports for convenient recall and access “on-the-go” ... Warehouse was built using client feedback to assist ...
Breaking Biology Technology:Nerium International Receives Direct Selling Association Membership 2Nerium International Receives Direct Selling Association Membership 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 2DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 3DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation 4Novogen Regains Full Compliance with NASDAQ Listing Rule 2Novogen Regains Full Compliance with NASDAQ Listing Rule 3
... ,, BEIJING, China , May ... or the "Company") a leading developer,manufacturer, and distributor of Shengmingsu brand ... ("PRC"), today announced its,financial results for the quarter ended ... 2010 Highlights, -- Revenue increased 100.5% to $24.9 ...
... RESEARCH TRIANGLE PARK, N.C. , May 12 The International ... Trials and Statistics Unit, is running the Intergroup Exemestane Study (IES).  IES ... early breast cancer and a median follow-up period of 91 months. ... from multiple centers. , , ...
... schedule , , , ... , , ... announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a ... of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and ...
Cached Biology Technology:Yongye International Announces First Quarter 2010 Results 2Yongye International Announces First Quarter 2010 Results 3Yongye International Announces First Quarter 2010 Results 4Yongye International Announces First Quarter 2010 Results 5Yongye International Announces First Quarter 2010 Results 6Yongye International Announces First Quarter 2010 Results 7Yongye International Announces First Quarter 2010 Results 8Yongye International Announces First Quarter 2010 Results 9Yongye International Announces First Quarter 2010 Results 10Yongye International Announces First Quarter 2010 Results 11Yongye International Announces First Quarter 2010 Results 12Yongye International Announces First Quarter 2010 Results 13Yongye International Announces First Quarter 2010 Results 14Max Neeman International Signs Agreement for Data Management/EDC of Large Phase IV Trials from Multiple Sites 2Resverlogix Completes Dosing for ASSERT Trial 2Resverlogix Completes Dosing for ASSERT Trial 3Resverlogix Completes Dosing for ASSERT Trial 4Resverlogix Completes Dosing for ASSERT Trial 5